Liraglutide effective for Weight loss in Patients With Severe Mental Illness
The prevalence of overweight and obesity is 2-3 times higher among people with schizophrenia than in the general population. In a recent study, researchers have reported that liraglutide potentially reduced the BMI, waist circumference and improves HbA1c when compared with placebo. The study findings were published in the journal Diabetes, Obesity & Metabolism on February 02, 2021.
Weight gain occurs early in the natural history of schizophrenia with a significant proportion of people with first-episode psychosis being overweight before treatment. Substantial weight gain, often more than 7%, occurs rapidly within 6-8 weeks after antipsychotic treatment initiation. Although previous studies suggest a potential use of GLP-1 receptors agonists to treat antipsychotic-induced weight gain, the doses used were the diabetes doses rather than obesity dose. Therefore, researchers of the Moorgreen Hospital, UK conducted a study to investigate the feasibility and acceptability of using liraglutide 3.0 mg daily to address this problem.
It was a double‐blind, randomised, placebo‐controlled pilot trial in 47 adults with schizophrenia, schizoaffective, or first‐episode psychosis prescribed antipsychotic medication who were overweight or obese. Researchers administered once-daily subcutaneous liraglutide or placebo, titrated to 3.0 mg daily, for 6 months. The major outcome assessed was recruitment, consent, retention and adherence. They also assessed weight, HbA1c and Brief Psychiatric Rating Scale.
Key findings of the study were:
• Among 799 screened patients, 44% were not eligible and 28% were unable to contact. The authors mentioned that the commonly stated reason why eligible candidates declined to participate related to the study-specific medication and protocol (n= 50). Finally, 47 participants were randomised, with 79% completing the trial.
• Upon analysis, researches noted that participants in the liraglutide arm had lost a mean 5.7±7.9 kg compared with no significant weight change in the placebo group (treatment difference −6.0 Kg).
• They also noted that the BMI, waist circumference and HbA1c reduced in the intervention group.
The authors concluded, "This study supports the need for a larger randomised controlled trial to evaluate the use of liraglutide (maximum dose 3.0 mg daily) in the management of obesity in people with severe mental illness".
For further information:
https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14334
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.